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SUMMARY 
Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease, peculiar to the 
extremely preterm infant, born at the early stages of lung development. Up to 40% of 
the infants below 29 weeks’ gestation are diagnosed with BPD, while the composite 
outcome death and/or BPD occurs in 65% of the infants below 29 weeks’ gestation. 
Despite the continuous advances of perinatal care, BPD remains a significant burden of 
extreme prematurity, because it lacks a safe and effective treatment and/ or prevention 
strategies. 
In the past few years, increasing insight into stem cell biology has generated excitement 
about the potential of stem cells to regenerate damaged organs. Among stem cells, 
mesenchymal stromal (stem) cells (MSCs) have attracted much attention because of 
their ease of isolation, multilineage potential, and immunomodulatory properties. 
Perivascular cells (PCs) from diverse human tissues give rise to adherent multilineage 
progenitor cells that exhibit all the features of MSCs and may embody the precursors of 
MSCs. MSCs and PCs may represent a novel therapeutical option for so far untreatable 
diseases, including BPD. 
While the definitive prevention of BPD could only be obtained by avoiding preterm birth, 
prenatal and postnatal preventive efforts are also directed at the reduction of the other 
stressors that may worsen the injury to the developing lung.  
The present thesis is a collection of studies aimed at investigating the potential use of 
MSCs and PCs in the treatment of BPD and evaluating the possible role of probiotic 
supplementation and mother’s own milk (MOM) diet in the prevention of BPD. 
In chapter I, we summarize and discuss the current state of knowledge on BPD 
pathophysiology 
and the potential therapeutic targets, with special emphasis on the role of MSCs and 
PCs. 
In chapter II we tested the potential of MSCs and their precursors (PCs) in preventing 
and treating the oxygen-induced lung injury in a murine model of BPD. We showed that 
MSCs and PCs are able to prevent and restore features of BPD in the hyperoxia-induced 
lung injury in rats with long term safety and efficacy. We investigated the homing of the 
cells, showing that it is minimal. As a consequence we proved that the media where 
cells are cultured, called conditioned medium (CdM) has similar effects as the whole cell 
therapy in preventing and treating the oxygen-induced lung injury. 
In Chapter III we performed a Cochrane meta-analysis to analyze the studies that have 
tested the possible role of MSCs in the treatment of BPD. We did not find any RCT or 
quasi-RCT that fulfilled the inclusion criteria. However, several trials are underway.  
In Chapter IV we performed a systematic review and meta-analysis to test the potential 
of probiotics in preventing BPD. Fifteen randomized controlled trials (4782 infants; 
probiotics: 2406) were included. None of the included studies assessed BPD as the 
primary outcome. Meta-analysis confirmed a significant reduction of necrotizing 
enterocolitis (NEC)  and an almost significant reduction of late-onset sepsis (LOS). In 
contrast, meta-analysis could not demonstrate a significant effect of probiotics on BPD, 
defined either as oxygen dependency at 28 days of life (relative risk (RR) 1.01, 95% CI 
0.91 to 1.11, p = 0.900, 6 studies) or at 36 weeks of postmenstrual age (RR 1.07, 95% CI 
0.96 to 1.20, p = 0.203, 12 studies). Meta-regression did not show any significant 
association between the RR for NEC or LOS and the RR for BPD.  
In Chapter V we performed a systematic review and meta-analysis to test the potential 
of MOM in preventing BPD. Fifteen studies met the inclusion criteria (4,984 infants, 
1,416 BPD cases). The use of exclusive MOM feedings was associated with a significant 
reduction in the risk of BPD (RR 0.74, 95% CI 0.57–0.96, 5 studies). In contrast, meta-
analysis could not demonstrate a significant effect on BPD risk when infants were fed 
with a mixed diet of MOM and formula milk.  
Finally, in chapter VII, we discuss and put into perspective the findings of this thesis. 
We also  present two future studies. In the first one we aim to explore the MSC potency, 
function, stemness, aging, differentiation capacity and extracellular vesicles production 
under different perinatal conditions (i.e. chorioamnionitis, pregnancy induced 
hypertension, diabetes, IUGR) as compared to healthy pregnancy at different gestational 
ages.  
The other one is a systematic review to advance the understanding of the antecedents 
of BPD, in particular the vascular disorders of the placenta.  
